Merck & Co. Inc. / Inspire Pharmaceuticals, Inc.

Ophthalmic Disorders (Bacterial Conjunctivitis, Dry Eye, Allergic Conjunctivitis, Glaucoma)

$106M Inspire 2010 ophthalmic revenue (per pre-deal disclosure)

Disease Overview

Front-of-eye disorders — bacterial and allergic conjunctivitis, dry eye disease, and glaucoma — are among the highest-volume indications in ophthalmology, with US dry-eye prevalence alone reaching roughly 20 million adults. Topical drug delivery is the dominant therapeutic modality, and integrated specialty eye-care sales forces are the primary commercial moat.

Competitive Landscape

In April 2011 the US ophthalmic prescription market was led by Allergan (Restasis for dry eye, Lumigan/Alphagan for glaucoma, Acuvail), Alcon/Novartis (Patanol/Pataday allergy, Travatan, Vigamox), Bausch & Lomb (Besivance, Lotemax), Pfizer (Xalatan, then losing exclusivity), and Merck's existing glaucoma business (Cosopt, Trusopt, Timoptic). Inspire's portfolio gave Merck (1) AzaSite — azithromycin 1% ophthalmic solution for bacterial conjunctivitis, the lead in-line product, (2) US co-promotion economics on Allergan's Restasis (cyclosporine 0.05% emulsion) — at that time the only US prescription dry-eye therapy, eventually a >$1.4B brand before generics, (3) Elestat (epinastine) for allergic conjunctivitis, (4) Saflutan/tafluprost — preservative-free prostaglandin analog for glaucoma under FDA review, and (5) royalty streams on Restasis and Diquas in Japan. Merck paid $5.00/share cash (~$430M, 26% premium) and explicitly framed Inspire as an instant US ophthalmic specialty sales-force plus a complementary product line that broadened Merck's existing glaucoma franchise. Inspire had pivoted away from pulmonary therapeutics earlier in 2011 after the failure of its cystic fibrosis program — context the financial press noted as reducing the target's negotiating leverage. Merck later divested or settled around AzaSite (including a 2018 off-label promotion settlement), and the broader ophthalmology footprint was effectively wound down as Merck reprioritized oncology and vaccines.